The following NCCTG cancer treatment clinical trials are currently active. You may click on the trial number to link to a detailed description on PDQ, the National Cancer Institute's Web site for clinical trials.
| 0825 | Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma |
| N0272 | Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI-571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma |
| N0572 | A Phase I/II Trial of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma |
| N0574 | A Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in the Management of Patients with One to Three Cerebral Metastases |
| N0577 | Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma |
| N057K | Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma |
| N0776 | Phase II Trial of Avastin in Combination with Sorafenib in Recurrent Glioblastoma Multiforme |
| N0779 | Phase II Study of Vorinostat (SAHA) in Combination with Bortezomib (PS-341) in Patients With Recurrent Glioblastoma Multiforme |
For more information, please discuss these trials with your physician, contact the NCCTG Operations Office or contact an NCCTG treating location near you.
Return to list of Cancer Treatment Trials
© Copyright 2008, NCCTG